Maternal Infection and Psychosis

Two grief experts expose the hidden health, social, and economic toll of bereavement—and the policy gaps leaving millions of grieving Americans unsupported.

Learn how the inhibition constant and 5-HT2A binding explain LSD effects—and why potent atypical antipsychotics may rapidly end a bad trip.

FDA hearing spotlights debates over psychedelic therapy: who administers, how to prove efficacy, and how to track safety as approvals near.

New US adult ADHD guidance nears publication, promising clearer diagnosis, comorbidity screening, and clinician training to curb misdiagnosis.

New research maps an mPFC–zona incerta circuit that drives punishment-resistant binge eating and hints at personalized brain stimulation targets for better treatment.

Phase 3 BLOOM tests 48-hour at-home oral brexanolone for rapid postpartum depression relief, with tighter monitoring after prior trial issues.

FDA clears Simtriyo, first NDSRI stimulant for ADHD ages 6 and older, as millions return to school—see what this means for treatment.

Phase 2 MOONLIGHT-1 shows JNJ-5120/PIPE-307 misses day‑5 MADRS improvement in MDD, yet remains well tolerated as J&J reviews next steps.